Latest News

Government Funding Bill Supports New SMA Research to Address Unmet Needs

March 25, 2024
Posted in , ,

Cure SMA’s year-long advocacy campaign to educate Congress and the Administration about the unmet needs of individuals with spinal muscular atrophy (SMA) has concluded with a major legislative victory. This […]

Read More ›

Cure SMA Awards $114,000 Grant to Michael Tellier, PhD, at the University of Leicester in the United Kingdom

March 21, 2024
Posted in , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA biology. Our Scientific Advisory Board […]

Read More ›

Apitegromab Linked to Improved Outcomes for Those with Spinal Muscular Atrophy

March 12, 2024
Posted in , ,

The study included 58 individuals with SMA types 2 and 3 who were treated with IV apitegromab for 52 weeks. At 36 months, treatment resulted in statistically significant improvements in […]

Read More ›

Cure SMA Awards $150,000 Grant to Allison Ebert, PhD, at The Medical College of Wisconsin

March 8, 2024
Posted in , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in SMA biology. Our Scientific Advisory Board […]

Read More ›

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

March 6, 2024
Posted in ,

  New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously […]

Read More ›

Novartis Presents New Data on Safety and Efficacy of Zolgensma, Including Maintained and Improved Motor Milestones in Older and Heavier Children with SMA

March 4, 2024
Posted in ,

  The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the […]

Read More ›
Scroll to Top